Methoxyacetylfentanyl. Report on the risk assessment of 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl] acetamide in the framework of the Council Decision on new psychoactive substances
Tallennettuna:
Methoxyacetylfentanyl. Report on the risk assessment of 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl] acetamide in the framework of the Council Decision on new psychoactive substances. Serie: Risk Assessments n. 30, Lisboa, European Monitoring Centre for Drugs and Drug Addiction, 2018, 58 p.
Ref.
537972
Sijainti:
SIIS Archivo
Palabras clave:
Drogodependencias, Drogas de síntesis, Acción contra las drogodependencias, Evaluación, Riesgo, Factor de riesgo, Efectos, Salud, Toxicidad, Tráfico de drogas, Delincuencia, Normativa, Unión Europea
Drogodependencias, Drogas de síntesis, Acción contra las drogodependencias, Evaluación, Riesgo, Factor de riesgo, Efectos, Salud, Toxicidad, Tráfico de drogas, Delincuencia, Normativa, Unión Europea
Samankaltaisia teoksia: Methoxyacetylfentanyl. Report on the risk assessment of 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl] acetamide in the framework of the Council Decision on new psychoactive substances
- Cyclopropylfentanyl. Report on the risk assessment of N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl] cyclopropanecarboxamide in the framework of the Council Decision on new psychoactive substances
- Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances
- EMCDDA-Europol Joint Report on a new psychoactive substance: 25I-NBOMe (4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine)
- RISK ASSESSMENT REPORT OF A NEW PSYCHOACTIVE SUBSTANCE: 4-METHYLMETHCATHINONE (MEPHEDRONE) IN ACCORDANCE WITH ARTICLE 6 OF COUNCIL DECISION 2005/387/JHA ON INFORMATION EXCHANGE, RISK ASSESSMENT AND CONTROL OF NEW PSYCHOACTIVE SUBSTANCES
- 5-(2-Aminopropyl)indole (5-IT). Report on the risk assessment of 5-(2-aminopropyl)indole in the framework of the Council Decision on new psychoactive substances
- REPORT ON THE RISK ASSESSMENT OF BZP IN THE FRAMEWORK OF THE COUNCIL DECISION ON NEW PSYCHOACTIVE SUBSTANCES